Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel

Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel

Dual antithrombotic therapy (DAT) without aspirin reduces bleeding compared with triple antithrombotic therapy (TAT) in patients with atrial fibrillation who have undergone percutaneous coronary intervention, without apparently increasing ischemic events. A prospective pharmacodynamic study was perf...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mark A. Sammut, Mohammed E. F. Rahman, Claire Bridge, Jessica Hanson, Heather Judge, Bethany Lynch, Emily Maz, Hannah McMellon, Janet Middle, Georgia Williamson, William A. E. Parker, Justin Lee, Robert F. Storey
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Platelets
Subjects:	Acute coronary syndrome aspirin atrial fibrillation dual antithrombotic therapy ticagrelor triple antithrombotic therapy
Online Access:	https://www.tandfonline.com/doi/10.1080/09537104.2025.2507037
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bioanalytical method development, in-vivo pharmacokinetic evaluation, ex-vivo platelet aggregation inhibition activity of a novel solid dispersion formulation of ticagrelor
by: Abhishek Srivastava, et al.
Published: (2025-02-01)

Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?
by: Jacek Kubica, et al.
Published: (2025-06-01)

The role of dual antithrombotic strategy (low-dose rivaroxaban + aspirin) in therapy: Joint consensus document of the Hungarian Society of Angiology and Vascular Surgery (MAÉT), the Hungarian Society of Cardiology (MKT) and the Hungarian Stroke Society (MST)
by: Zoltán Járai, et al.
Published: (2025-02-01)

Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?
by: S. G. Kanorskii
Published: (2020-07-01)

Prevention of thrombotic complications in patients in the postoperative period of total hip and knee arthroplasty: efficacy and safety
by: A. M. Ushanova, et al.
Published: (2023-05-01)

Development of a quality by design based eco-friendly RP-HPLC method for Ticagrelor and Aspirin
by: Shivani Jani, et al.
Published: (2025-06-01)

Antithrombotic therapy in clinical practice
by: J.A. Ker, et al.
Published: (2003-03-01)

ANTITHROMBOTIC PROPHYLAXIS REPEATED PREECLAMPSIA IN PATIENTS WITH THROMBOPHILIA
by: E. V. Zhuravleva
Published: (2016-06-01)

Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis)
by: O. V. Reshetko, et al.
Published: (2020-11-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE
by: E. N. Dankovtseva, et al.
Published: (2015-12-01)

ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS
by: V. A. Sulimov
Published: (2016-01-01)

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY
by: M. Yu. Gilyarov
Published: (2015-12-01)

ANTITHROMBOTIC PROPHYLAXIS RECURRENT PREECLAMPSIA IN PATIENTS WITH THROMBOPHILIA
by: E. V. Zhuravleva, et al.
Published: (2016-06-01)

New trends in antithrombotic therapy in vascular neurology
by: E. A. Shirokov
Published: (2021-09-01)

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
by: Fadel Bahouth, et al.
Published: (2025-05-01)

Antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention: what has changed in the guidelines in 2020?
by: E. P. Panchenko
Published: (2020-12-01)

PROSPECTS FOR THE TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION
by: V. A. Sulimov, et al.
Published: (2016-01-01)

SAFETY OF LONG-TERM THERAPY WITH WARFARIN: HEMORRHAGE FREQUENCY AND CLINICAL PREDICTORS (results of a prospective 15-year follow-up)
by: E. S. Kropacheva, et al.
Published: (2017-05-01)

Antithrombotic Therapy and the Nearest Forecast of Pulmonary Embolism in Rutine Clinical Practice (Data of the Regional Vascular Center of the Ryazan Region)
by: N. N. Nikulina, et al.
Published: (2022-05-01)

Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines
by: L. L. Bershtein, et al.
Published: (2021-11-01)

Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology
by: O. N. Tkacheva, et al.
Published: (2021-05-01)

The study of antithrombotic efficacy, safety and tolerability of aspirin generic in patients with coronary heart disease
by: Khomaziuk T.A., et al.
Published: (2013-10-01)

Antithrombotic strategies after transcatheter aortic valve replacement a network meta-analysis
by: Mengxiao Shi, et al.
Published: (2025-05-01)

Severe Upper Gastrointestinal Bleeding in Patients on Antithrombotic Therapy
by: Ji Hye Kwak, et al.
Published: (2017-03-01)

Comparative analysis of intramyocardial autotransplantation of postnatal stem cells from peripheral blood and adipose tissue in patients with acute phase of myocardial infarction, ST segment elevation, after effective thrombolytic reperfusion and coronary artery stenting
by: A. N. Kharlamov, et al.
Published: (1970-01-01)

COVID-19: hemostatic parameters and specifics of antithrombotic treatment
by: I. S. Yavelov, et al.
Published: (2020-07-01)

Up-to-date potential of antithrombotic therapy in patients with coronary artery disease and diabetes
by: O. D. Ostroumova, et al.
Published: (2020-09-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

Appropriate Antithrombotic Management for Older Adults Living with Dementia
by: Barbara Resnick, et al.
Published: (2025-03-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Multicenter retrospective comparison of safety and efficacy among three antithrombotic regimens following TAVI
by: Yu Ren, et al.
Published: (2025-06-01)

Dual versus single antiplatelet therapy in patients with nonminor ischemic stroke: a meta-analysis
by: Izabela Orlandi Môro, et al.
Published: (2025-02-01)

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?
by: O. V. Averkov, et al.
Published: (2018-09-01)

AGE AND EFFECTIVENESS AND SAFETY OF VARIOUS ANTITHROMBOTIC THERAPY VARIANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
by: V. I. Shevelev, et al.
Published: (2013-02-01)

Embolic myocardial infarction. Literature review and own research results
by: S. A. Boldueva, et al.
Published: (2020-07-01)

Cancer history and mortality risk in acute myocardial infarction: Insights from the Japan AMI registry
by: Ayumi Adachi, et al.
Published: (2025-08-01)

Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation
by: V. I. Petrov, et al.
Published: (2019-03-01)

RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
by: I. V. Grajfer, et al.
Published: (2015-12-01)

ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY)
by: V. I. Petrov, et al.
Published: (2015-09-01)